MedTrace Logo

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors

NCT06963502 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 762

Last updated 2025-05-09

No results posted yet for this study

Summary

This is a Phase Ib study that will evaluate the Safety, Tolerability , Pharmacokinetics, Activity and Immunogenicity of HS-10370 in Combination With Other Anti-cancer Therapies in Chinese patients with KRAS G12C mutation advanced or metastatic solid tumors, especially in and Colorectal cancer(CRC) and non-Small cell lung cancer (NSCLC).

Conditions

Interventions

DRUG

HS-10370

Participants will receive HS-10370 dose 1 administered orally

DRUG

HS-20117

Participants will receive HS-20117 given as dose 3 intravenous infusion(IV) once every 14-day cycle.

DRUG

Adebrelimab

Participants will receive Adebrelimab intravenous infusion(IV) once every 21-day cycle

DRUG

Capecitabine

Participants will receive Capecitabine administered orally

DRUG

Oxaliplatin

Participants will receive Oxaliplatin intravenous infusion(IV) once every 21-day cycle.

DRUG

Folinic Acid, Fluorouracil and Oxaliplatin/Irinotecan

Participants will receive Folinic Acid, Fluorouracil and Oxaliplatin/Irinotecan intravenous infusion(IV) once every 14-day cycle.

DRUG

HS-20093

Participants will receive HS-20093 intravenous infusion(IV) once every 21-day cycle

DRUG

platinum (cisplatin or carboplatin)

Participants will receive platinum (cisplatin or carboplatin) administered IV in 21-day cycles.

Sponsors & Collaborators

  • Jiangsu Hansoh Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-30
Primary Completion
2028-12-31
Completion
2030-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06963502 on ClinicalTrials.gov